Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
Jiahong Zheng, Bang Li, Yingqi Wu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8407-8427
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance
Yongxia Zhu, Tong Xia, D Chen, et al.
Drug Resistance Updates (2023) Vol. 72, pp. 101016-101016
Open Access | Times Cited: 23
Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions
Chao Tong, Xiujin Chang, Fangui Qu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116212-116212
Closed Access | Times Cited: 11
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers
Kimberly J. Briggs, Kevin M. Cottrell, Matthew R. Tonini, et al.
Translational Oncology (2025) Vol. 52, pp. 102264-102264
Open Access | Times Cited: 1
From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy
Ian Sarvary, Mikkel Vestergaard, Loris Moretti, et al.
Journal of Medicinal Chemistry (2025)
Open Access | Times Cited: 1
Cycling back to folate metabolism in cancer
Younghwan Lee, Karen H. Vousden, Marc Hennequart
Nature Cancer (2024) Vol. 5, Iss. 5, pp. 701-715
Open Access | Times Cited: 7
Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents
Juan Zhang, Xuliang Liu, Na Sa, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116341-116341
Closed Access | Times Cited: 6
In silico protein structural analysis of PRMT5 and RUVBL1 mutations arising in human cancers
Majd Al-Marrawi, Ruben C. Petreaca, Renee A. Bouley
Cancer Genetics (2025)
Open Access
Research Progress in DNA Damage Response (DDR)-Targeting Modulators: from Hits to Clinical Candidates
Binbin Cheng, Zongbao Ding, Yun Hong, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117347-117347
Closed Access
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design
Kevin M. Cottrell, Douglas A. Whittington, Kimberly J. Briggs, et al.
Journal of Medicinal Chemistry (2025)
Open Access
PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer
Jiaoti Huang, Bei-Ning Qiao, Yixin Yuan, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 4
Open Access
Aberrant miRNA expression and protein arginine methyltransferase 5 (PRMT5) in cancer: A review
Saı̈d Sif, Majdi Al Alawneh
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2025) Vol. 1872, Iss. 3, pp. 119923-119923
Open Access
Alternative Splicing Analysis Reveals Adrenergic Signaling as a Novel Target for Protein Arginine Methyltransferase 5 (PRMT5) in the Heart
S.F. Jiao, Yimeng Zhang, Xiao Yang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2301-2301
Open Access
PADI4 facilitates stem‐like properties and cisplatin resistance through upregulating PRMT2/IDs family in oesophageal squamous cell carcinoma
Zeyu Wang, Hao Wu, Zhaoxing Li, et al.
Clinical and Translational Medicine (2025) Vol. 15, Iss. 3
Open Access
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
Liping H. Pettus, Matthew P. Bourbeau, Nuria Tamayo, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
PPDPF is not a key regulator of human pancreas development
Markus Breunig, Meike Hohwieler, Jasmin Haderspeck, et al.
PLoS Genetics (2025) Vol. 21, Iss. 4, pp. e1011657-e1011657
Open Access
Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma
Zhihao Liu, Min Lin, Chenyu Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6313-6326
Closed Access | Times Cited: 4
Design, synthesis and biological evaluation of novel naphthoquinothiazole derivatives as potent antitumor agents through inhibiting STAT3
Dongmei Fan, Pingxian Liu, Z.-Q. Li, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107565-107565
Closed Access | Times Cited: 2
TBL2 Promotes Tumorigenesis via PRMT5/WDR77‐Mediated AKT Activation in Breast Cancer
Xiuqing Lu, Chao Zhang, Lewei Zhu, et al.
Advanced Science (2024)
Open Access | Times Cited: 2
Discovery of tetrahydroisoquinolineindole derivatives as first dual PRMT5 inhibitors/hnRNP E1 upregulators: Design, synthesis and biological evaluation
Wenhui Chu, Na Yang, Jinhe Zhang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115625-115625
Closed Access | Times Cited: 6
PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma
Devendra Kumar, Stuti Jain, Donald W. Coulter, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5855-5855
Open Access | Times Cited: 6
Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease
Philip W. Brownjohn, Azedine Zoufir, Daniel J. O’Donovan, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors
Yu‐Ting Chen, Zekun Wang, Junjie Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116171-116171
Closed Access | Times Cited: 1
An update on small molecule compounds targeting synthetic lethality for cancer therapy
Jiaxiang Luo, Yang Li, Yiwen Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 278, pp. 116804-116804
Closed Access | Times Cited: 1
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2
Jianwei Wei, Qiongyu Shi, Bang Li, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 18, pp. 16056-16071
Closed Access | Times Cited: 1
CD38 symmetric dimethyl site R58 promotes malignant tumor cell immune escape by regulating the cAMP-GSK3β-PD-L1 Axis
Lin Liang, Chunxue Yue, Wentao Li, et al.
Heliyon (2024) Vol. 10, Iss. 19, pp. e37958-e37958
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top